Mikhail Blagosklonny Uses Anti-Aging Drug in Cancer Treatment

It may seem unusual for an oncologist to be using the same type of medicine that plastic surgeons are using, but that is exactly what Mikhail Blagosklonny is doing with the patients that he has. He tries to make sure that he can help people out with the issues that they have and with cancer that they are trying to fight. One of the jobs of an oncologist is to make sure that they are protecting their patients while they are going through the treatment. They must be able to protect their well-being and must work to make sure that their immune systems are not compromised at all. Mikhail Blagosklonny has always wanted to come up with new ways to boost the immune system and make things easier for people who are trying to get over the things that they are doing. This has all led to him looking for new methods of treatment.

When Mikhail Blagosklonny was using his own publication, Oncotarget, he found that he could use an anti-aging drug to help treat the immune problems that come from cancer treatment. He has been confident in his skills and all of this has led to him being able to try different things. It has made it easier for him to make the right choices and for him to be able to help other people out with the issues that they have. When Mikhail Blagosklonny first tried the anti-aging drug on his patients, he knew that it was going to work and that he would be able to increase the good cells that they had in their body similar to how he was doing things to make things better for them in different areas of treatment.

One of the things about Oncotarget is that it allows people from different disciplines of medicine to connect with each other. They can all benefit from each other and they can make sure that things are going to work out for each other. Those who are a part of the peer review publication have found out more information about what they are able to do and this has allowed them the chance to make things better for each other.

All of the doctors who are a part of Oncotarget know what they are doing in their own practice. They have often studied it for many years and they are experts at making their patients well again. They have to try and make sure that they are able to help other people with the methods that they have. When they can do this, it makes things better for them. When they can share that information, it makes things even better for other doctors who have other practices.

To know more click here

Dr. Seigall’s Efforts To Cure Cancer


Dr. Clay Seigall is the Co-Founder and CEO of Seattle Genetics. He also enjoys finding interesting articles online and sharing them on his official blog. A recent one he shared was about the learning myths that people have and a quiz to see if you hold them. In the article, experts talk about how most people are ignorant of research on learning. One of the key points of the article is that 90% of people think students should learn information in their own “learning” style. Research into learning actually says, even though that sounds intuitive, it’s completely wrong according to research.

Another article that Dr. Siegall posted is a new, better way to clean up oil spills. The article describes an invention, called the Flame Refluxer, is actually quite simple and incorporates copper wool, in between layers of thin copper, with copper coils attached to the top. The device is put over an oil spill and it’s set on fire; the coils collect the heat and the device dissipate it which leads to a complete burn of the spill.

Dr. Seigall founded Seattle Genetics in 1998 after several years of research and development into drugs that treat cancer. The first drug that he developed at Seattle Genetics that was approved by the FDA is Adcetris which treats several forms of Lymphoma. His company also has several anti-cancer drugs in the pipeline at various stages of development. He also announced in 2016 that he has ambitious plans as he seeks to develop 12 more drugs and hire more than a hundred people.

Under Dr. Seigall’s leadership, Seattle Genetics has grown into a company that already has more than 800 employees. Besides the headquarters of the company in Bothell, Washington, it also has an office in Switzerland that opened in 2016. Their drug Adcetris achieved sales of $226 million in 2015 and was on pace for sales of $255 to $275 million for 2016.

In addition to his work at Seattle Genetics, Dr. Seigall plays a larger role in the cancer research community. He sits on the board of several pharmaceutical companies including Alder BioPharmaceuticals and Mirna Therapeutics.